David Shaw’s Genocea Biosciences, Inc. GNCA Stock Holding History

David Shaw’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-10,747	Closed	-$31K	–	4313
2019 Q3	$31K	Sell	10,747 -10,653	-50%	-$36.4K	﹤0.01%	3746
2019 Q2	$84K	Buy	+21,400	New	+$112K	﹤0.01%	3561
2018 Q3	–	Sell	-3,711	Closed	-$25K	–	4109
2018 Q2	$25K	Buy	3,711 +1,757	+90%	+$13.1K	﹤0.01%	3664
2018 Q1	$16K	Buy	+1,954	New	+$16.2K	﹤0.01%	3441
2015 Q4	–	Sell	-2,487	Closed	-$136K	–	4054
2015 Q3	$136K	Buy	2,487 +1,101	+79%	+$109K	﹤0.01%	3576
2015 Q2	$152K	Buy	+1,386	New	+$129K	﹤0.01%	3618

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

David Shaw's GNCA Position: Q4 2019 in Review

David Shaw sold out of Genocea Biosciences, Inc. (GNCA) in Q4 2019, closing a stake of 10,747 shares — an estimated $31K sold.

David Shaw first reported a position in GNCA in Q2 2015 and held it in 6 quarters. The position peaked at $152K in Q2 2015. 34 funds tracked by Wall St. Rank hold GNCA as of Q4 2019.

David Shaw reported no remaining Genocea Biosciences, Inc. position as of Q4 2019 after selling out during the quarter.
David Shaw sold 10,747 Genocea Biosciences, Inc. shares in Q4 2019, an estimated $31K.
David Shaw first reported a position in Genocea Biosciences, Inc. in Q2 2015 and held it in 6 quarters.
David Shaw's Genocea Biosciences, Inc. position peaked at $152K in Q2 2015.
34 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q4 2019.

Based on D.E. Shaw & Co's 13F filing for Q4 2019, filed 14 Feb 2020.